Румунія -
румунська -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
bortezomib hetero 3,5 mg
pharmadox healthcare ltd. - malta - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice alte antineoplazice
Румунія -
румунська -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
bortezomib koanaa 3,5 mg
wave pharma limited - marea britanie - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice alte antineoplazice
Молдова -
румунська -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
difluzol 100 mg capsule
kievmedpreparat sap - fluconazolum - capsule - 100 mg
Молдова -
румунська -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
difluzol 150 mg capsule
kievmedpreparat sap - fluconazolum - capsule - 150 mg
Молдова -
румунська -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
difluzol 50 mg capsule
kievmedpreparat sap - fluconazolum - capsule - 50 mg
Європейський Союз -
румунська -
EMA (European Medicines Agency)
lenalidomide accord
accord healthcare s.l.u. - lenalidomidă - mielom multiplu - imunosupresoare - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomida accord în asociere cu dexametazona este indicat pentru tratamentul mielomului multiplu la pacienții adulți care au primit cel puțin un tratament anterior. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
Молдова -
румунська -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
xatiza 60 mg/1,5 ml concentrat şi solvent pentru soluţie perfuzabilă
msn laboratories pvt. limited - cabazitaxelum - concentrat şi solvent pentru soluţie perfuzabilă - 60 mg/1,5 ml
Європейський Союз -
румунська -
EMA (European Medicines Agency)
polivy
roche registration gmbh - polatuzumab brentuximab - limfom cu celule b - agenți antineoplazici - polivy în combinație cu bendamustina și rituximab este indicat pentru tratamentul pacienților adulți cu recăderi/refractară diffuse large b-cell lymphoma (dlbcl) care nu sunt candidați pentru transplant de celule stem hematopoietice. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).
Румунія -
румунська -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
bortezomib koanaa 3,5 mg
wave pharma limited - marea britanie - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice alte antineoplazice
Європейський Союз -
румунська -
EMA (European Medicines Agency)
lenalidomide mylan
mylan ireland limited - lenalidomidă - mielom multiplu - imunosupresoare - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).